PERSPECTIVE THERAPEUTICS, INC. Perspective Therapeutics, Inc.
Equities
CATX
US46489V1044
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 USD | -1.25% |
|
+5.33% | +293.03% |
Presenter SpeechJohan Spoor (Executives)All right. Good morning, everybody. Welcome, and thank...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Companyâs core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Companyâs segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.58
USD
Average target price
1.6
USD
Spread / Average Target
+1.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +293.03% | 927M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Transcript : Perspective Therapeutics, Inc. - Analyst/Investor Day
